Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Fiche publication

Date publication

décembre 2022

Journal

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre , Dr GAIDDON Christian , Dr GROSS Isabelle , Dr GUERIN Eric , Dr JUNG Alain , Dr ROMAIN Benoit , Dr MELLITZER Georg , Dr VENKATASAMY Aina , Dr MIGUET Laurent

Tous les auteurs :
Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36536236

Résumé

Gastric cancer (GC) is an aggressive disease due to late diagnosis resulting from the lack of easy diagnostic tools, resistances toward immunotherapy (due to low PD-L1 expression), or chemotherapies (due to p53 mutations), and comorbidity factors, notably muscle atrophy. To improve our understanding of this complex pathology, we established patient-derived xenograft (PDX) models and characterized the tumor ecosystem using a morpho-functional approach combining high-resolution imaging with molecular analyses, regarding the expression of relevant therapeutic biomarkers and the presence of muscle atrophy.